Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC

作者
Alexandria TM Lee,Misako Nagasaka
出处
期刊:Lung cancer [Dove Medical Press]
卷期号:Volume 15: 169-176 被引量:5
标识
DOI:10.2147/lctt.s492126
摘要

Mutations in KRAS G12C are among the more common oncogenic driver mutations in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug Administration (FDA) granted accelerated approval to adagrasib, a small molecule covalent inhibitor of KRAS G12C, for the treatment of patients with locally advanced or metastatic KRAS G12C mutant NSCLC who received at least one prior systemic therapy based on promising results from phase 1 and 2 trials wherein adagrasib demonstrated a median PFS of 6.5 months. Results from the phase 3 KRYSTAL-12 trial were recently presented, showing benefit with adagrasib compared to docetaxel, with participants in the adagrasib group demonstrating a PFS of 5.5 months compared to 3.8 months in the docetaxel group. However, these results fall short of the 6-month PFS benchmark that had seemed achievable from what had been seen in phase 1 and 2 trials, mirroring similarly disappointing results from the CodeBreaK 200 trial wherein sotorasib, the first-in-class KRAS G12C inhibitor, also failed to meet the 6-month benchmark also thought to be possible when examining earlier trials. These results raise the question of adagrasib's true value in the second-line treatment setting and compel us to explore more potent novel therapies, combination therapies, and more as we seek to break the 6-month PFS barrier in the treatment of KRAS G12C mutant NSCLC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
醉熏的伊完成签到,获得积分10
刚刚
冷酷雪碧完成签到 ,获得积分10
1秒前
1秒前
MJMO完成签到,获得积分10
1秒前
maxiaole完成签到,获得积分0
1秒前
2秒前
朱晖完成签到,获得积分10
2秒前
俞孤风完成签到,获得积分10
3秒前
DW的应助被科研通管家采纳,获得10
4秒前
cdercder的应助被科研通管家采纳,获得10
4秒前
cdercder的应助被科研通管家采纳,获得10
4秒前
nanfeng完成签到 ,获得积分10
4秒前
轩辕中蓝完成签到 ,获得积分10
4秒前
Maestro_S的应助被科研通管家采纳,获得10
4秒前
慕青的应助被科研通管家采纳,获得10
5秒前
Gallop完成签到,获得积分10
5秒前
汉堡包的应助被科研通管家采纳,获得10
5秒前
赘婿的应助被科研通管家采纳,获得10
5秒前
asdfqwer完成签到,获得积分0
5秒前
Firsterchao的应助被科研通管家采纳,获得10
5秒前
cdercder的应助被科研通管家采纳,获得10
5秒前
hj123完成签到,获得积分10
5秒前
5秒前
所所的应助被科研通管家采纳,获得10
5秒前
夜白的应助被科研通管家采纳,获得20
5秒前
嵩杨梅完成签到 ,获得积分10
5秒前
充电宝的应助被科研通管家采纳,获得10
5秒前
cdercder的应助被科研通管家采纳,获得10
6秒前
玛卡巴卡完成签到 ,获得积分10
6秒前
Firsterchao的应助被科研通管家采纳,获得10
6秒前
慕青的应助被科研通管家采纳,获得10
6秒前
6秒前
科研通AI6.3的应助被子慕采纳,获得10
7秒前
Leohp完成签到,获得积分10
7秒前
wyx完成签到,获得积分10
8秒前
LILI完成签到,获得积分10
8秒前
王祈瑾完成签到,获得积分10
8秒前
执着的钢笔完成签到,获得积分20
9秒前
Baclear完成签到,获得积分10
10秒前
行者无疆完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809184
捐赠科研通 7776198
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479039